Abstract

Background:
Sepsis remains the main cause of morbidity and mortality worldwide. Early administration of appropriate antimicrobials is one of the most effective interventions for sepsis; however, antibiotic resistance in bacteria is growing continuously. Therefore, new complementary therapies are needed to treat sepsis. One of the recently studied complementary therapies is the administration of the mesenchymal stem cell (MSC) secretome. Several studies have shown that the secretome exerts immunomodulatory and antiinflammatory effects. However, the studies did not assess the clinical changes occurring in sepsis-induced rats.

Aim:
This study aimed to analyze the effect of TGF-β from the MSC secretome on sepsis scores in a murine model.

Methods:
Forty-eight rats were divided into 4 groups: healthy rats (rats without sepsis induction and therapy), control (300 µL saline + antibiotic), T1 (150 µL TGF-β from MSC secretome + antibiotic), and T2 (300 µL TGF-β from MSC secretome + antibiotic). The murine sepsis score (MSS) was observed every 6 hours for 48 hours. Data analysis was conducted using SPSS to examine the relationship between the effect of TGF-β from MSC secretome administration and the total mean of MSS. The value of p < 0.05 was considered significant.

Results:
Administering 150 µL of TGF-β from MSC secretome reduced the total mean MSS compared with the control group at the 42nd hour of observation (p = 0.017).

Conclusion:
Our research found that TGF-β from MSC secretome improved the sepsis score in sepsis-induced rats.

Key words: Mesenchymal stem cell; Murine sepsis score; TGF-β; Umbilical cord.